ARCHIVES

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Better Access Key To Higher Survival For African-Americans With Colon Cancer

August 30, 2002

Soviet Exchanges Rise And Fall With Politics

August 23, 1991

NCI’s Weinstein Said He Never Pressured Researcher

November 3, 1995

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

September 8, 2006

NCI To Send Eight To AIDS Conference, Few Will Attend Cancer Meetings

February 28, 1992

In Brief: Rogers On AHF Board; GAO Says Legislation May Needed For Hospice Reimbursement

March 23, 1979